RESUMEN
Objectives: To evaluate the technique of use of metered dose inhaler (MDI) in patients of asthma or chronic obstructive pulmonary disease (COPD) patients at a tertiary health care hospital. Materials and methods: This was a cross-sectional observational study conducted in the patients of bronchial asthma and COPD who were prescribed MDI. The method to use MDI was assessed by using checklist made by WHO Guide to Good Prescribing. Results: A total of 193 patients (128 COPD, 65 asthma) were included. Majority of patients (95%) were educated by the treating physician for the use of inhalational technique of MDI. Majority of patients (98.4%) followed the step to place the lips tightly around the mouthpiece. While the least followed steps were coughing up as much sputum as possible (14.5%), breathing out through nose (15%) and rinsing the mouth after use (22.8%). Conclusion: Few steps of MDI use were missed in majority of the patients. This can be improved by demonstration and by providing awareness by the health care worker.
RESUMEN
Present study evaluates the effects of antipsychotic medications on metabolic parameters in patients suffering from psychiatric illness. The study was carried out at tertiary care teaching hospital, department of psychiatry after obtaining written informed consent from the patients. They were randomized into three groups - Group I (n=31) (haloperidol 10 mg/day, orally), Group II (n=34) (risperidone 4-6 mg/day, orally) and Group III (n=38) (olanzapine 10 mg/day, orally). Metabolic parameters [fasting blood sugar (FBS), post prandial blood sugar (PP2BS), glycosylated haemoglobin (HbA1c), serum cholesterol, triglyceride, low density lipoprotein (S.LDL) and high density lipoprotein (S.HDL)] were measured at the end of 3 and 6 months. Data was analysed using a suitable statistical tests. In group II significant changes (p<0.05) were observed in FBS, HBA1C, cholesterol, S.LDL and S.HDL while in group III significant changes (p<0.05) were observed in all the metabolic parameters at the end of 6 months. In group III, FBS, PP2BS, HbA1C, Serum cholesterol, triglyceride and S.LDL levels were increased 9.41%, 7.09%, 8%, 6.25%, 7.68% and 9.92% respectively, at the end of 6 months. Patients treated with haloperidol showed minimum changes in metabolic parameters at the end of 6 months. Olanzapine is associated with more disturbances in metabolic parameters as compared to risperidone and haloperidol.